Trial reportThe Journal of clinical psychiatry2015
Initial response as a predictor of 12-week buprenorphine-naloxone treatment response in a prescription opioid-dependent population.
Trial report in The Journal of clinical psychiatry, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00316277 (A Two-Phase Randomized Controlled Clinical Trial of Buprenorphine/Naloxone Treatment Plus Standard Medical Management or Enhanced Medical Management for Opioid Analgesic Dependence), which is not on this map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Two-Phase Randomized Controlled Clinical Trial of Buprenorphine/Naloxone Treatment Plus Standard Medical Management or Enhanced Medical Management for Opioid Analgesic Dependence
Who cites it
16 citing papers in PubMed, 23 citations in OpenAlex.
- Investigating craving as an indicator of early response to buprenorphine treatment among adults with opioid use disorder.Journal of consulting and clinical psychology · 2026Trial
- Extended-Release 7-Day Injectable Buprenorphine for Patients With Minimal to Mild Opioid Withdrawal.JAMA network open · 2024Trial
- Association between dynamic dose increases of buprenorphine for treatment of opioid use disorder and risk of relapse.Addiction (Abingdon, England) · 2022Trial
- Correlates of Long-Term Opioid Abstinence After Randomization to Methadone Versus Buprenorphine/Naloxone in a Multi-Site Trial.Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology · 2018Trial
- The Prescription Opioid Addiction Treatment Study: What have we learned.Drug and alcohol dependence · 2017Trial
- Identifying Optimal Thresholds for Early Opioid Use Frequency in Predicting Buprenorphine Outcomes.The Journal of clinical psychiatry · 2026Article
- Protocol for harmonization of randomized trials testing the addition of behavioral therapy to buprenorphine for opioid use disorder.Drug and alcohol dependence reports · 2024Article
- Buprenorphine & methadone dosing strategies to reduce risk of relapse in the treatment of opioid use disorder.Drug and alcohol dependence · 2022Article
- The changing opioid crisis: development, challenges and opportunities.Molecular psychiatry · 2021Review
- Measurement-based care using DSM-5 for opioid use disorder: can we make opioid medication treatment more effective?Addiction (Abingdon, England) · 2019Article
- The Role of Behavioral Interventions in Buprenorphine Maintenance Treatment: A Review.The American journal of psychiatry · 2017Review
- Shelter-Based Opioid Treatment: Increasing Access to Addiction Treatment in a Family Shelter.American journal of public health · 2017Article
- Dropout in clinical trials of pharmacological treatment for methamphetamine dependence: the role of initial abstinence.Addiction (Abingdon, England) · 2017Article
- Predictors of early dropout in outpatient buprenorphine/naloxone treatment.The American journal on addictions · 2016Article
- Dependence on Prescription Opioids.Deutsches Arzteblatt international · 2016Review
- Prescription Opioid Misuse, Abuse, and Treatment in the United States: An Update.The American journal of psychiatry · 2016Review
Corrections and comments
- Commented on by
Authors and funding
7 authors at 1 institution in 1 country.
Funding
Abstract
objectiveInitial medication response has been shown to predict treatment outcome across a variety of substance use disorders, but no studies have examined the predictive power of initial response to buprenorphine-naloxone in the treatment of prescription opioid dependence. We therefore conducted a secondary analysis of data from the Prescription Opioid Addiction Treatment Study to determine whether initial response to buprenorphine-naloxone predicted 12-week treatment outcome in a prescription opioid-dependent population.
methodUsing data from a multisite, randomized controlled trial of buprenorphine-naloxone plus counseling for DSM-IV prescription opioid dependence (June 2006-July 2009), we conducted a secondary analysis to investigate the relationship between initial medication response and 12-week treatment outcome to establish how soon the efficacy of buprenorphine-naloxone could be predicted (N = 360). Outcomes were determined from the Substance Use Report, a self-report measure of substance use, and confirmatory urinalysis. Predictive values were calculated to determine the importance of abstinence versus use at various time points within the first month of treatment (week 1, weeks 1-2, 1-3, or 1-4) in predicting successful versus unsuccessful treatment outcome (based on abstinence or near-abstinence from opioids) in the last 4 weeks of buprenorphine-naloxone treatment (weeks 9-12).
resultsOutcome was best predicted by medication response after 2 weeks of treatment. Two weeks of initial abstinence was moderately predictive of treatment success (positive predictive value = 71%), while opioid use in both of the first 2 weeks was strongly predictive of unsuccessful treatment outcome (negative predictive value [NPV] = 84%), especially when successful outcome was defined as total abstinence from opioids in weeks 9-12 (NPV = 94%).
conclusionsEvaluating prescription opioid-dependent patients after 2 weeks of buprenorphine-naloxone treatment may help determine the likelihood of successful outcome at completion of the current treatment regimen.
trial registrationClinicalTrials.gov identifier: NCT00316277.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.